Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, today announced that
management will present at the upcoming Jefferies 2019 Global Healthcare
Conference taking place June 4-7, 2019 in New York, NY.
The Company’s presentation will be Friday, June 7, 2019 at 12:30 p.m. ET.
Interested parties can access a live webcast of the presentation via a
link from Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations,
which will also host a recorded replay available afterwards.
About Zymeworks Inc.
Zymeworks is a clinical-stage biopharmaceutical company dedicated to the
development of next-generation multifunctional biotherapeutics. The
Company’s suite of therapeutic platforms and its fully integrated drug
development engine enable precise engineering of highly differentiated
product candidates. Zymeworks’ lead clinical candidate, ZW25, is a novel
Azymetric™ bispecific antibody currently in Phase 2 clinical
development. The Company’s second clinical candidate, ZW49, is a
bispecific antibody-drug conjugate currently in Phase 1 clinical
development and combines the unique design and antibody framework of
ZW25 with Zymeworks’ proprietary ZymeLink™ cytotoxic payload. Zymeworks
is also advancing a deep preclinical pipeline in immuno-oncology and
other therapeutic areas. In addition, its therapeutic platforms are
being leveraged through strategic partnerships with nine
biopharmaceutical companies. For more information, visit www.zymeworks.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005141/en/
Copyright Business Wire 2019